BioMarin Pharmaceuticals BMRN Investment Purchases
Investment Purchases at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInvestments.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's investment purchases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's investment purchases?
- BioMarin Pharmaceuticals (BMRN) reported investment purchases of $25.79M in Q1 2026.
- How has BioMarin Pharmaceuticals's investment purchases changed year-over-year?
- BioMarin Pharmaceuticals's investment purchases decreased by 71.1% year-over-year, from $89.27M to $25.79M.
- What is the long-term trend for BioMarin Pharmaceuticals's investment purchases?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's investment purchases has grown at a -21.5% compound annual growth rate (CAGR), from $937.14M to $355.88M.
- What does investment purchases mean?
- Cash spent on buying investment securities.
- How do you interpret investment purchases?
- Higher outflows indicate a focus on treasury management and capital preservation, whereas lower outflows may suggest cash is being prioritized for R&D or operations.
- How does investment purchases compare across companies?
- Standard for companies with significant cash balances; peers typically balance this against R&D spending requirements.